Positive phase III data in hand, Myokardia heads to the FDA.
Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.
Behind Lilly’s LY-CoV555 come numerous biopharma antibody projects bidding to enter clinical development.
Non-US big biopharma stocks led the way in the third quarter, suggesting that those looking for investment gains would do best to search further afield.
Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.
A look at sector share prices in the opening three months of 2019 reveals a resurgent big pharma and a strong showing from the world’s other large drug makers, with US…